about
Folate system correlations in DNA microarray data.The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongationBiochemical systems analysis of genome-wide expression data.Recent data obtained by pulsed-field gel electrophoresis suggest two types of double-strand breaks.12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors.On systems and control approaches to therapeutic gain.Equilibrium model selection: dTTP induced R1 dimerizationA phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.Hematological toxicity after robotic stereotactic body radiosurgery for treatment of metastatic gynecologic malignancies.Automated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibriums: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data.Mass action models versus the Hill model: an analysis of tetrameric human thymidine kinase 1 positive cooperativity.How to use the computing environment R to analyze ATP-induced ribonucleotide reductase R1 hexamerization data.Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.A novel data-driven prognostic model for staging of colorectal cancer.On model ensemble analyses of nonmonotonic data.Genetic alterations of the cohesin complex genes in myeloid malignancies.Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system.Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic MalignanciesRadiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancersEvaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.dNTP Supply Gene Expression Patterns after P53 Loss.p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesp53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.Etiology and treatment of hematological neoplasms: stochastic mathematical models.Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation.Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of SeliciclibSphingoid base metabolism in yeast: mapping gene expression patterns into qualitative metabolite time course predictionsMethods for analysis of DNA fragment distributions on pulsed field gel electrophoretic gels.Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.A mathematical model of human thymidine kinase 2 activity.Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine.Estimation of the target stem-cell population size in chronic myeloid leukemogenesis.Size distributions of misrejoining DNA fragments in irradiated cells.A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.
P50
Q24810624-C94C10C1-55B6-43E8-8202-8A162C8D9D13Q28240978-15A7484C-F88C-46C3-8851-A7F87CB45EC2Q30625916-DDAFAC5B-61DB-4657-A9D6-D12DDB8CBF8DQ32156679-249C7685-EB41-4715-9DD0-A6D1EE04AD1DQ33225216-2F04FABE-F934-4676-8150-BB93E17647B7Q33241062-68F9968E-E3ED-429D-9970-B93F571B3FD3Q33318133-10548E34-28FB-4D8E-B4BB-3C7339A112E1Q33363422-88D25309-BD14-4C41-930C-4BD79C57848FQ33400982-3B6351CA-389E-4587-8D88-EBAE80EC337CQ33517852-3DA7402E-8188-41C3-9145-81CE0FC1E68CQ33562894-8B9AC8BD-CE54-4728-A4E8-1D89E6D52439Q33603139-9F4C59F7-B555-4719-A64D-8F1EC155B078Q33652165-D33C58BA-1698-4A89-BDEC-DB91F4890D5FQ34021493-2868D829-419C-42AD-AAB4-02E7862872B8Q34150280-EB26B20B-6677-4D58-8B83-A5C3C851ABE6Q34170374-BA05B966-803B-432C-A598-130F8529FC36Q34302170-C7AE8DBE-8BE7-414D-BDAA-3FF7FED1A671Q34482362-D4B0A214-B443-4E4B-B1F5-FBD753C70A53Q34662652-41FFB2B3-3460-4532-9554-CE3278E365CAQ35183982-D5261C15-CF14-4268-A90C-BD5CA0712BFCQ35796011-131EAC04-6B69-4FD4-B7A7-2D6F5F2E9FCFQ36112585-3F744C20-56BD-4F56-B45B-E0218BE4B1F0Q36432360-D72F2716-1612-40FD-9A50-40D5DBDBD5B8Q36848202-AC20CEF2-8296-46CE-8013-EA28E9FD5B0CQ36890276-D9ED2C12-B9CB-472E-8644-DBE93EFAB7F9Q38284015-73EA9C5D-BBFC-4B76-BCED-1DEC2EB6DCE5Q38351012-2CAB1885-23FB-4F02-964F-F78371CE8450Q38640027-0F2BEE89-CD2C-4E81-A5BB-EACAA9D8A5B6Q38877559-FDD2E8AA-6A8F-4251-B78C-EE8C49B56CA1Q39803315-6D46527E-4EC8-489B-9403-0DEB5F351B20Q41131528-6DDF01A5-DF0D-4CE5-8E75-90C7324DED50Q41230119-8A8E17FD-6FA5-4185-B04C-F06BDBF786E6Q41813473-C502312C-C01B-433A-B967-B08BECB71DFAQ44010009-B896F1BE-3E3D-4C49-B3A1-762B24A104E6Q46848282-D46293CB-02C9-40B0-9F32-EA039513C3BCQ46854633-73015AE3-36C1-49C4-8BE1-F414450E1F2EQ46882726-60BBAD7C-1CB9-405E-8623-73AEEF4053CDQ47255406-897025F9-3BE3-4164-9CF7-74BC7B7D4C3BQ47287711-A3D7D535-CEA6-4040-BCCE-226BE2E219ABQ48368776-8029C08A-B920-4080-AA88-E9FEEAC6D02C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tomas Radivoyevitch
@ast
Tomas Radivoyevitch
@en
Tomas Radivoyevitch
@es
Tomas Radivoyevitch
@nl
Tomas Radivoyevitch
@sl
type
label
Tomas Radivoyevitch
@ast
Tomas Radivoyevitch
@en
Tomas Radivoyevitch
@es
Tomas Radivoyevitch
@nl
Tomas Radivoyevitch
@sl
prefLabel
Tomas Radivoyevitch
@ast
Tomas Radivoyevitch
@en
Tomas Radivoyevitch
@es
Tomas Radivoyevitch
@nl
Tomas Radivoyevitch
@sl
P106
P108
P2038
Tomas_Radivoyevitch
P21
P2456
P31
P496
0000-0002-9701-1851